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Background: The leukocyte common antigen (CD45) is a 
transmembrane-type protein tyrosine phosphatase that has 
five isoforms. Methods: We generated seven murine mAbs 
against human CD45 by injecting cells from different origins, 
such as human thymocytes, PBMCs, and leukemic cell lines. 
By using various immunological methods including flow cy-
tometry, immunohistochemistry, and immunoprecipitation, 
we evaluated the reactivity of those mAbs to CD45 of thy-
mus as well as tonsil lysates. Furthermore, we transiently 
transfected COS-7 cells with each of gene constructs that 
express five human CD45 isoforms respectively, and exam-
ined the specificities of the mAbs against the transfected 
isoforms. Results: In case of thymocytes, lymphocytes, and 
monocytes, all the seven mAbs demonstrated positive re-
activities whereas none was reactive to erythrocytes and 
platelets. The majority of immune cells in formalin-fixed par-
affin-embedded thymus and tonsil tissues displayed strong 
membranous immunoreactivity, and the main antigen was de-
tected near 220 kDa in all cases. Among the mAbs, four 
mAbs (AP4, DN11, SHL-1, and P6) recognized a region com-
monly present in all the five isoforms. One mAb, YG27, rec-
ognized four isoforms (ABC, AB, BC, and O). Two mAbs, P1 
and P14, recognized the isoforms that contain exon A en-
coded regions (ABC and AB). Conclusion: In this study, we 
confirmed that AP4, DN11, SHL-1, YG27 and P6, are mAbs 
reactive with the CD45 antigen whereas P1 and P14 are re-
active with the CD45RA antigen.
[Immune Network 2011;11(2):114-122]
INTRODUCTION
The  leukocyte  common  antigen  (CD45),  the  most  common 
hematopoietic lineage marker, belongs to a family of trans-
membrane-type protein tyrosine phosphatases with high mo-
lecular masses of 180 to 220 kDa (1-7). Using many mono-
clonal antibodies (mAbs) against CD45, it was revealed that 
CD45  comprises  5∼10%  of  lymphocyte  surface  proteins, 
known as one of the most abundant glycoproteins expressed 
on  lymphocytes  (1).
    Charbonneau  et  al.  observed  a  significant  sequence  sim-
ilarity  between  the  tandem  repeats  in  the  cytoplasmic  do-
mains of two proteins, CD45 and protein tyrosine phospha-
tase (PTP) 1B (8). Subsequent cloning of CD45 at the cDNA 
and genomic levels revealed several interesting characteristics 
about the primary structure of this molecule (9-11). The ex-
tracellular domain of human CD45 varys in length (391∼552 
amino acids) depending on which combination of exons are 
alternatively used to form the CD45 mRNA. The three alter-
natively used exons of CD45, exons 4, 5, and 6, encode pep-
tide  segments  designated  A,  B,  and  C,  respectively.  In  hu-
man, five different isoforms of CD45 mRNAs have been iso-
lated, which contain all three exons (ABC isoform), two of 
the three exons (AB and BC isoform), only one exon (B iso-
form),  or  no  exons  (O  isoform),  respectively  (9-11).  All  of 
the isoforms (schematically shown in Fig. 1) have the same 
8  amino  acids  at  their  amino-terminus,  which  are  followed 
by the various combinations of A, B, and C peptides (66, 47, Characterization of CD45 mAbs
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Figure 1. The structures of the five 
human CD45 isoforms derived from 
cDNA cloning.
and  48  amino  acids  long,  respectively).  The  remaining  re-
gions (the 383-amino-acid extracellular region, the 22-amino- 
acid  transmembrane  peptide,  and  the  707  amino-acid-cyto-
plasmic  region)  have  the  identical  sequences  in  the  all 
isoforms.  The  N-terminal  region  of  CD45  is  known  to  be 
heavily glycosylated (12). Therefore, alternative mRNA splic-
ing of CD45 can result in a significant degree of heterogeneity 
in the extracellular domain due to differential O-linked glyco-
sylation  as  well  as  the  structure  changes  of  the  molecule.
  A s  a  r e s u l t  o f  t h e  v a r i a b i l i t y  o f  t h e  N - t e r m i n a l  r e g i o n  o f  
CD45, mAbs raised against the CD45 protein recognize either 
all of the CD45 isoforms (CD45 mAb), or only a subset of 
the isoforms (“restricted” CD45R mAb). Thus, the suffix RA, 
RB, or RO indicates the requirement of the amino acid resi-
dues corresponding to exon A (RA), exon B (RB), or a lack 
o f  a m i n o  a c i d  r e s i d u e s  c o r r e s p o n d i n g  t o  e x o n  A ,  B  a n d  C 
(RO) for the CD45 epitope expression, respectively. Accord-
ingly, CD45 mAb binds to all isoforms, whereas CD45RA mAb 
binds to ABC and AB isoforms, CD45RB mAb binds to ABC, 
AB,  BC,  and  B  isoforms,  and  CD45RO  mAb  binds  only  to 
the  180  kDa  isoform,  which  lacks  any  of  the  alternatively 
used exons (O isoform). In this report, we analyzed the char-
acteristics  of  seven  murine  mAbs  raised  against  the  human 
leukocyte  common  antigen  (CD 4 5 )  ( A P 4 ,  D N 1 1 ,  S H L - 1 ,  
YG27, P1, P6, and P14). By using these antibodies, we were 
able to not only immunoprecipitate the CD45 isoforms, but 
also differentiate cellular expression profiles of the isoforms. 
In  addition,  by  transiently  transfecting  COS-7  cells  with  the 
plasmids expressing CD45 isoforms, we examined the bind-
ing  specificities  of  the  mAbs  to  those  isoforms.
MATERIALS AND METHODS
Production of monoclonal antibody
Seven murine mAb (AP4, DN11, SHL-1, YG27, P1, P6, and 
P14) were developed by immunizing Balb/c mice with vari-
ous  native  human  cellular  immunogens.  Briefly,  AP4  was 
raised by immunizing PHA-activated human peripheral blood 
mononuclear cells (PBMC), and other antibodies were raised 
with  cells  from  various  origins:  thymic  stromal  cells  (for 
DN11), Jurkat (for SHL-1), thymocytes (for YG27), and resting 
human  PBMCs  (for  P1,  P6,  P14).  After  6  week-old  Balb/c 
mice were immunized i.p. with each immunogen (10
7 cells), 
the spleens were removed, and 10
8 spleen cells were fused 
with 10
7 SP2/0-Ag14 mouse myeloma cells using polyethylene 
glycol (PEG 4000, Rahway, NL). The hybrids were cultured 
in flat-bottom microculture trays at 37
oC in an atmosphere of 
humidified  air  conditioning  5%  CO2,  and  selected  in  HAT 
media. After 10 days, culture supernatant was harvested and 
tested  for  reactivity  to  human  lymphocytes  by  indirect  im-
munoflurescence method using flow cytometry. Seven of the 
resulting hybridoma clones, whose supernatant was reactive 
t o  h u m a n  l y m p h o c y t e s ,  w e r e  n a m e d  A P 4 ,  D N 1 1 ,  S H L - 1 ,  
YG27, P1, P6, and P14. Cells from a microculture well were 
subcloned by limiting dilution, and the culture supernatant of 
the clones was tested for antibody production. For production 
of the mAb in ascites form, pristane-treated Balb/c mice were 
injected  i.p.  with  5×10
6  hybridoma  cells,  and  the  ascites 
were collected after 1 week of injection. mAb was purified 
from  ascites.
Determination of antibody isotype
The  isotype  of  AP4,  DN11,  SHL-1,  YG27,  P1,  P6,  and  P14 Characterization of CD45 mAbs
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were determined by enzyme immunoassay using mouse mon-
oclonal subtyping kit EK-5050 (Hyclone, Utah, USA). Isotyp-
ing  was  performed  with  rabbit  anti-murine  isotype-specific 
antisera (IgG1, IgG2a, IgG2b, IgG3, IgM, Kappa, Lambda) fol-
lowed by peroxidase-labeled goat anti-rabbit IgG as the sec-
ondary antibody. with the addition of o-phenylene diamine 
and hydrogen peroxide substrate, positive samples turned an 
intense  yellow.
Cells and cell lines
We screened the expression of the AP4, DN11, SHL-1, YG27, 
P1,  P6,  and  P14  antigen  on  the  freshly  isolated  peripheral 
blood  erythrocytes,  lymphocytes,  monocytes,  granulocytes 
and platelet from the healthy volunteers. The tumor cell lines 
were purchased from American type culture collection (atcc, 
Rockville,  MD)  and  cultured  in  RPMI-1640  medium  supple-
mented  with  10∼20%  fetal  calf  serum.
Flow cytometry
Fresh cell suspension from patients and healthy donors were 
examined for the AP4, DN11, SHL-1, YG27, P1, P6, and P14 
antigen  expression  by  flow  cytometric  analysis  using  AP4, 
DN11, SHL-1, YG27, P1, P6, and P14 mAb. Cells (10
6) were 
incubated with saturating amounts of the purified AP4, DN11, 
SHL-1, YG27, P1, P6 and P14 or a control immunoglobulin 
for 30 min at 4
oC. Thereafter, cells were washed two times 
with  phosphate-buffered  saline  (PBS),  incubated  with  fluo-
rescein  isothiocyanate (FITC)-conjugated  goat anti-mouse as 
secondary antibody for 20 min at 4
oC and washed two times 
with PBS. Cells were analyzed on a FACS (COULTER, USA). 
Samples containing over 20% AP4, DN11, SHL-1, YG27, P1, 
P6,  and  P14-positive  cell  were  regarded  as  positivity.
Immunohistochemical study
W e  s c r e e n e d  t o n s i l  a n d  t h y m u s  o b t a i n e d  f r o m  t h e  s u r g i c a l  
pathology files of Chungbuk National University Hospital. All 
tissues had been fixed in 10% formalin and embedded in par-
affin, and indirect immunoperoxidase technique and antigen 
retrieval  method  by  microwave  heating  were  employed 
(13,14).
    Chromogen  used  as  3,3’-diaminobenzidine.  Counterstain 
was  not  performed  and  the  reaction  pattern  was  analyzed 
based  on serial  hematoxylin-eosin stained sections.  We  de-
fined positive cells by staining pattern along cell membrane.
Immunoprecipitation
Fresh cell suspensions of tonsil from patient of chronic tonsil-
litis and of thymus from patient of congenital heart disease 
were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1% NP-40 and 1 mM PMSF [phenyl methyl sulfonyl fluo-
ride]).  Lysates  were  precleared  successively  with  protein 
A-Sepharose  and  rabbit  anti-mouse  IgG  bound  to  protein 
A-Sepharose at 4
oC for 4 h. 20μl of seven mAb coupled to 
protein A-Sepharose were used for immunoprecipitation with 
precleared cell lysates at 4
oC overnight. Immune complexes 
were washed with a buffer containing 0.25% NP-40, 5 mM 
P M S F ,  1 0  m M  T r i s ,  p H  8 . 0 ,  1 5 0  m M  N a C l ,  5  m M  K I ,  a n d  
5  m M  E D T A .  A f t e r  e x t e n s i v e  w ashing,  the  immunoprecipi-
tates were eluted by boiling for 5 min in SDS sample buffer 
and  analyzed  on  6%  SDS-PAGE  under  non-reducing  con-
dition, with appropriate molecular weight markers. After elec-
trophoretic  transfer  of  immune  complex,  the  nitrocellulose 
was  blocked  with  5%  skimmed  milk  in  Tris-buffered  saline 
(10 mM Tris-HCl, 150 mM N aCl, pH 7.6) containing 0.05% 
Tween-20 (TBST). The bound peroxidase was visualized us-
ing  the  ECL  chemoluminescence  detection  system  (Amer-
sham).
Production of tansfectants
The cDNAs encoding the five CD45 isoforms, which were in-
serted into the cloning site of a slightly modified version of 
the pcDL-SRα296 expression plasmid (15), termed pSP65-SRα2. 
The resultant plasmids were used to transiently transfect the 
COS-7  cells  by  the DEAE-dextran method  (16).  COS-7  cells 
were harvested by trypsination and were seeded into 10 cm 
plate at a final density of 1×10
6 cells/plate. After 12 h, the 
cells were washed twice with prewarmed phosphate-buffered 
saline (PBS) (138 mM NaCl, 2.6 mM KCl, 10 mM Na2HPO4, 
1.8  mM  KH2PO4,  pH  7.4)  and  were  fed  with  transfection 
mixture (DME, 0,25 mg/ml DEAE dextran, 0.1 M Tris, pH 7.3 
containing DNA), using 4 ml/plate for 12 h. After 12 h, the 
cells were washed with prewarmed PBS and were incubated 
with  10%  DMSO  reagent  at  room  temperature.  3  min  after 
addition of the 10% DMSO reagent, the medium was removed 
by  aspiration  and  the  monolayers  were  washed  with  pre-
warmed PBS. The cells were subsequently incubated in cul-
ture medium containing 0.1 mM chloroquin for 2 h 30 min. 
The cells were washed with prewarmed PBS, and incubated 
with fresh culture medium in CO2 atmosphere at 37
oC for 48 
h.  Resulting  cells  express  each  of  the  CD45  isoforms.  The 
binding specificities of seven mAb were characterized by flow Characterization of CD45 mAbs
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Table I. Flow cytometric analysis of seven mAbs in hematopoietic cells
mAb
Cell
Lymphocyte Monocyte Granulocyte Erythrocyte Platelet
AP4 ＋(88.2%) ＋(96.0%) ＋(93.7%) −−
DN11 ＋(87.2%) ＋(98.6%) ＋(86.7%) −−
SHL-1 ＋(85.7%) ＋(99.2%) ＋(94.5%) −−
YG27 ＋(81.8%) ＋(90.9%) ＋(37.2%) −−
P1 ＋(82.2%) ＋(82.7%) −− −
P6 ＋(82.9%) ＋(98.9%) ＋(93.5%) −−
P14 ＋(83.8%) ＋(90.5%) −− −
Table II. Flow cytometric analysis of seven mAbs in leukemic cell
lines
mAb
Cell line (Origin)
U937
(Histiocytic 
lymphoma)
K562
(Erythroid 
leukemia)
Molt-4
(T-ALL)
AP4 ＋(96.7%) ＋(39.4%) ＋(98.6%)
DN11 ＋(95.0%) ＋(30.9%) ＋(97.2%)
SHL-1 ＋(98.6%) ＋(35.5%) ＋(92.0%)
YG27 ＋(93.9%) ＋(89.8%) ＋(78.8%)
P1 ＋(82.5%) −−
P6 ＋(97.9%) ＋(37.4%) ＋(99.2%)
P14 ＋(77.2%) −−
cytometric analysis using the COS-7 cells that expressing the 
individual human CD45 isoforms. The anti-CD45/FITC (T29/ 
33; DAKO, Denmark) was used as a positive control. Samples 
containing over 10% AP4, DN11, SHL-1, YG27, P1, P6, and 
P14-positive  cell  were  regarded  as  positivity.
RESULTS
Determination of antibody isotype
The  isotype  of  AP4,  DN11,  SHL-1,  YG27,  P1,  P6,  and  P14 
mAb were determined by enzyme immunoassay. The isotype 
of AP4 was IgG2b whereas the isotypes of the other remain-
ing  mAbs  were  all  categorized  into  IgG1.
Reactivity of AP4, DN11, SHL-1, YG27, P1, P6, and 
P14 to hematopoietic cells
To  evaluate  the  recognition  profile  of  the  mAbs  in  various 
hematopoietic cells, normal human hematopoietic cells from 
peripheral  blood  were  analyzed  by  flow  cytometry.  Five 
monoclonal  antibodies  (AP4,  DN11,  SHL-1,  YG27,  and  P6) 
were  reactive  with  lymphocytes,  monocytes,  and  gran-
ulocytes,  but  not  with  erythrocytes  or  platelet.  Two  mono-
clonal  antibodies  (P1  and P14) were reactive with lympho-
cytes and monocytes, but not with granulocytes, erythrocytes, 
or  platelets  (Table  I).
Reactivity of AP4, DN11, SHL-1, YG27, P1, P6, and 
P14 to various leukemic cell lines
Similarly to the above experiment, we examined the recog-
nition profile of the mAbs in leukemic cells, U937 (Histiocytic 
lymphoma),  K562  (Erythroid  leukemia)  and  Molt-4  (T-ALL) 
cells. AP4, DN11, SHL-1, YG27, and P6 mAb were reactive 
with all of the tested leukemic cell lines. P1 and P14 were 
reactive with U937, but not with K562 or Molt-4 (Table II).
Reactivity to formalin fixed thymus and tonsil
To validate their clinical usage, the immunoreactivity of mAbs 
on  formalin-fixed  paraffin-embedded  human  tissue  was 
checked. All the seven mAbs displayed strong membranous 
immunoreactivity in nearly all cases of immune cells in for-
malin  fixed  paraffin  embedded  thymus  (Fig.  2)  and  tonsil 
(Fig.  3)  samples.
Characterization of seven mAb target antigen
To identify the antigen immuniprecipitated with these seven 
mAbs, lysates of thymus and tonsil were analyzed. The mo-
lecular weights of proteins recognized by AP4, DN11, SHL-1, 
YG27, and P6 were examined by immunoprecipitation using 
thymus lysates. AP4 recognized two proteins of 220 and 205 
kDa whereas DN11, SHL-1, YG27, and P6 recognized three 
proteins of 220,  205, and  190 kDa (Fig. 4). The molecular 
weight  of  the  antigen  recognized  by  P1  and  P14  was  de-
termined  by  immunoprecipitation  using  tonsil  lysates.  Two 
discrete bands of the antigen corresponded to two molecules Characterization of CD45 mAbs
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Figure 2. Reactivity of AP4 on formalin fixed thymus. All T cells of 
cortex (C) and medulla (M) were reactive with AP4. but, squamous 
cells of Hassall’s corpuscle (H) were not reactive with AP4.
Figure 3. Reactivity of P14 on formalin fixed tonsil. All lymphocytes 
of germinal center (G), mantle (M) and interfollicular (IF) area were
reactive with P14.
Figure 4. Immunoprecipitation of thymus lysates with AP4, DN11, 
SHL-1, YG27 and P6 mAb. Lane 1; AP4 lane 2; DN11 lane 3; SHL-1
lane 4; YG27 lane 5; P6. Cells were lysed in lysis buffer containing 
1% NP-40. precleared cell lysates were immunoprecipitated with AP4,
DN11, SHL-1, YG27 and P6 mAb. The immunoprecipitates were 
analyzed by SDS-PAGE (6%) under nonreducing condition.
Figure 5. Immunoprecipitation of tonsil lysates with P1 and P14 mAb.
Cells were lysed in lysis buffer containing 1% NP-40. Precleared cell
lysates were immunoprecipitated with P1 and P14 mAb. The 
immunoprecipitates were analyzed by SDS-PAGE (6%) under 
nonreducing condition. o f  a p p r o x i m a t e l y  2 2 5  a n d  2 0 0  k D a  ( F i g .  5 ) .
Transfection study
To confirm which isoform of CD45 is recognized by each of 
these seven mAbs, transfecton study was performed. In trans-
fection study, four mAb (AP4, DN11 (Fig. 6), SHL-1, and P6) 
bound to all five isoforms (the ABC isoform, AB isoform, BC 
isoform, B isoform and O isoform), one mAb (YG27) bound 
to four isoforms (the ABC isoform, AB isoform, BC isoform 
and O isoform) and two mAb (P1 (Fig. 7) and P14) bound 
to two isoforms that include exon A encoded sequences (the 
ABC isoform and AB isoform). In these results, we confirmed 
that AP4, DN11, SHL-1, YG27 and P6 are conventional CD45 
mAb  and  P1  and  P14  are  CD45RA  mAb  (Table  III).
DISCUSSION
In this report, we examined the specificities of seven mAbs 
raised in our lab by using transiently transfected COS-7 cells 
that express each of five CD 45 isoforms. Based on the bind-
ing patterns, the seven mAbs are classified into two groups: 
AP4, DN11, SHL-1, YG27, and P6 are CD45 mAbs whereas 
P1  and  P14  are  CD45RA  mAbs.  Because  of  their  abundant 
expression of hematopoietic cells, we were easily able to ob-
tain mAbs against CD45 by immunizing conventional cellular 
immunogen, such as thymocytes, PBMCs and leukemic cell 
lines,  but  mAb  against  CD45RB  or  CD45RO  could  not  be Characterization of CD45 mAbs
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Figure 6. Transfection study of DN11 mAb. Flow cytometric analysis of DN11 using COS-7 cells expressing the individual human CD45 isoforms.
DN11 bound to all five isoforms (the ABC isoform, AB isoform, BC isoform, B isoform and O isoform).
obtained.
    Based on the expression profiles of CD45 mAbs that were 
previously studied and reported, we classified the generated 
m A b s  b y  t h e i r  f l o w  c y t o m e t r i c  p a t t e r n s .  I n  f l o w  c y t o m e t r i c 
analysis of the seven mAb with hematopoietic cells, five mon-
oclonal antibodies (AP4, DN11, SHL-1, YG27 and P6) were 
reactive with lymphocytes, monocytes and granulocytes but 
not with erythrocytes and platelets (Table I). Two monoclonal 
antibodies (P1 and P14) were reactive with lymphocytes and 
monocytes but not with granulocytes, erythrocytes and plate-
lets (Table I). According to Leukocyte Typing V (17), CD45RB 
mAb  is  reactive  with  erythrocytes  and  CD45RA  mAb is  not 
reactive with granulocytes. Therefore, in terms of CD45 anti-
gen expression pattern recognized by seven mAbs, there is 
no CD45RB mAb at least and we supposed that P1 and P14 
s h o u l d  b e  a  C D 4 5 R A  m A b .  U 9 3 7  ( H i s t i o c y t i c  l y m p h o m a ) ,  
K562 (Erythroid leukemia). Molt-4 (T-ALL) were analyzed by 
flow cytometry. AP4, DN11, SHL-1, YG27 and P6 mAb were 
reactive with these all leukemic cell lines. P1 and P14 only 
were reactive with U937, but not with K562 and Molt-4 (Table 
II). According to Leukocyte Typing V (17), CD45RO mAb is 
not reactive with U937. Therefore, there is no CD45RO mAb 
among  seven  mAbs.  CD45RA  mAb  was  not  reactive  with 
K562 and Molt-4. Therefore, those data also support that P1 
and  P14  would  be  a  CD45RA  mAb.  In  terms  of  molecular 
weight analysis AP4, P1, and P14 were immunoprecipitated 
with two proteins of 220 and 205 kDa (Fig. 5). But DN11, 
SHL-1, YG27 and P6 recognized three proteins of 220, 205, 
and 190 kDa (Fig. 4). Above expression profiles and molec-
ular results also support that AP4, DN11, SHL-1, YG27 and 
P6 would be a conventional CD45mAb and P1 and P14 would 
be  a  CD45RA  mAb.
    In  order  to  confirm  those  findings,  we  transiently  trans-
fected COS-7 cells with each of 5 isoform cDNA constructs 
of CD45, and examined the specificities of the seven mAbs 
against the isoforms. Although the percentage of the positive 
ones against these mAbs among the transfected COS-7 cells 
appeared to be relatively low, we were able to classify their 
specificities  by  comparison  of  commercially  available  an-
ti-CD45 Abs with known specificity (Table III). Of the seven Characterization of CD45 mAbs
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Figure 7. Transfection study of P1 mAb. Flow cytometric analysis of P1 using COS-7 cells expressing the individual human CD45 isoforms.
P1 bound to two isoforms that include exon A encoded sequences (the ABC isoform and AB isoform).
Table III. Flow cytometric analysis of seven mAbs using transiently transfected COS-7 cells that express individual human leukocyte 
common antigens
Transfectant
mAb (%)
CD45Ab AP4 DN11 SHL-1 YG27 P1 P6 P14
Control 1.7 0.3 0.4 0.2 0.6 0.3 0.3 0.4
O 13.7 13.5 22.6 10.3 21.3 0.7 10.8 0.5
B 31.2 20.8 32.1 10.9 4.2 3.4 17.4 2.2
BC 29 24.9 15.1 19.3 16.5 5.6 19.9 2.3
AB 24.9 26.3 22.8 19.4 20.0 56.8 25.2 37
ABC 23.5 30.2 29.7 40.8 22.6 36.2 31.3 19.1
mAbs tested, four mAb (AP4, DN11 (Fig. 6), SHL-1, and P6) 
recognized  a  sequence  common  to  all  of  the  five  isoforms 
(ABC, AB, BC, B, and O) (Table III). One mAb (YG27) recog-
nized four isoforms (ABC, AB, BC and O), and two mAb (P1 
( F i g .  7 )  a n d  P 1 4 )  r e c o g n i z e d  i s o f o r m s  t h a t  i n c l u d e  e x o n  A 
encoded  sequences  (ABC  and  AB)  (Table  III).  Thus,  these 
results indicate that AP4, DN11, SHL-1, YG27 and P6 are an-
ti-CD45 mAbs whereas P1 and P14 are anti-CD45RA mAbs. 
Y G 2 7  m A b  u n u s u a l l y  r e v e a l e d  n e g a t i v e  r e a c t i v i t y  t o  C O S - 7  
cells  transfected  with  B  construct,  but  remaining  four  con-
structs revealed positive reactivity we categorized YG27 mAb 
a s  a  C D 4 5  m A b .
    Although the development of various CD45 mAbs has been 
previously  reported,  only  a  few  antibodies  against  CD45RB 
and CD45RO were successful. As expected, the majority of 
the mAbs that we developed recognized all isoforms, and on-
ly  two  mAbs  (P1  and  P14)  recognized  both  ABC  and  AB 
isoforms. None of mAbs recognizes B and O isoforms. It is Characterization of CD45 mAbs
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because the epitopes required for the generation of CD45RO 
or CD45RB mAbs might be heavily glycosylated, which proc-
ess is essential for the biological function of thymocytes, lym-
phocytes and leukemic cells (17-20). In case of using CD45 
antigens overproduced in E. coli, antibodies recognizing only 
the epitope composed of the polypeptide backbone will be 
produced, resulting in failure of antibody production that rec-
ognize the natural structure of the antigen. Accordingly, we 
utilized whole immune cell extract for immunization to pro-
duce practical antibodies for diagnostic or therapeutic usage 
in this study, but the generation of CD45RO or CD45RB mAbs 
was  not  successful.
    In immunohistochemical study, all the seven mAb showed 
strong membranous staining patterns in case of all the hema-
topietic cells in formalin-fixed paraffin-embedded thymus and 
tonsil samples (Figs. 2 and 3). This result indicates that these 
mAbs may be used singly or together for the detection and 
the  differential  diagnosis  of  hematopoietic  malignancies  in 
surgical  pathology  (13,14).
    Several key issues related to the physiological role of CD45 
isoforms  remain  mostly  unsolved,  such  as  the  identification 
of its extracellular ligands as well as intracellular substrates, 
and the mechanism responsible for regulation of CD45 cata-
lytic  activity,  albeit  a  few  limited  published  data  (17-21). 
These questions are currently being investigated using a wide 
range of technical approaches and cell systems, which seems 
to be more advanced by the development of various CD45 
mAbs. Currently, the modulation of CD45 function by mAbs 
has been suggested as an optional treatment to control auto-
i m m u n e  d i s e a s e s ,  t r a n s p l a n t  r e j e c t i o n ,  a n d  e v e n  c a n c e r  
(22-25). Therefore, the possibility of therapeutic significance 
of these seven mAbs should be evaluated in the near future. 
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